Allakos Inc.’s AK006 Disappoints in CSU; Company Pulls Plug
Allakos Inc.’s AK006 disappointed in a Phase 1 study of chronic spontaneous urticaria (CSU), and the Company will discontinue further clinical development of AK006. In the CSU cohort, 34 adult patients with moderate-to-severe CSU refractory to antihistamines with or without prior exposure to omalizumab were enrolled and randomized 2:1 to receive 720mg of intravenous AK006 […]